Chardan Research highlighted CRISPR Therapeutics reporting Phase 1a data for CTX310, an in vivo CRISPR-Cas9 therapy targeting ANGPTL3.
Published
Signal category
Research & Knowledge
Quote
“CRISPR Therapeutics (NASDAQ: CRSP) reported Phase 1a data for CTX310, an in vivo CRISPR-Cas9 therapy targeting ANGPTL3.”
— Chardan team
Company
Chardan
Where disruption banks. ™
- Industry
- Investment Banking
- Location
- New York, US
- Company size
- 100 employees
Chardan is an independent global investment bank specializing in SPACs, healthcare, and disruptive innovation spanning all sectors. Our range of services include capital raising, merger and acquisition advisory, strategic advisory, equity research, corporate access and institutional trading. Headquartered in New York City, Chardan is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: FINRA, SIPC, and NASDAQ. Disclaimer: Information posted on this Web site is believed to be reliable at the time of posting; Chardan Capital Markets, LLC and its affiliates cannot, however, guarantee the accuracy or completeness of such information or make any warranties with regard to the results to be obtained from its use. Information on this Web site is not intended to provide financial, legal, accounting or tax advice and should not be relied upon in that regard. Chardan Capital Markets, LLC and its affiliates are not responsible in any manner for direct, indirect, special or consequential damages howsoever caused, arising out of the use of this Web site or any of its content.
Founded 2002